Specialty Pharmacy: A Key to Organizational Success in Population Health Management

Scott Knoer, MS, PharmD, FASHP Chief Pharmacy Officer, Cleveland Clinic

Steve Rough, MS, RPh, FASHP Director of Pharmacy, University of Wisconsin Health

The speakers have no actual or potential Conflict of Interest in relation to this presentation.

The Big Picture

Patients spend 99% of their time in the community Medications are a cornerstone of population health management

Medication access & affordability is complex

Pharmacists interact with patients every month

Overview

- •What is specialty pharmacy and why is it relevant to population health?
- •UW Health's specialty pharmacy program
- •Cleveland Clinic's "secret sauce"
- •Proof of concept: improved quality, lower cost

What are we talking about when we say "Population Health"?

•The health outcomes of a group of individuals, including the distribution of such outcomes within the group - 2003




Kindig, DA, Stoddart G. (2003). <u>What is population health?</u> *American Journal of Public Health*, 93, 366-369 http://healthaffairs.org/blog/2015/04/06/what-are-we-talking-about-when-we-talk-about-population-health/ What are we talking about when we say "Specialty Pharmacy"?

Specialty Pharmaceuticals What are they?

- Very <u>expensive</u>: average prescription $cost^1 = $3,500$
- Number of patients growing quickly
 → 2% currently, expected to hit 5-6% by 2018
- •Initiated by a specialist & often require special handling
- Increasingly transitioning to therapies that can be selfadministered in the home
- Require significant clinician accountability to work

\$130B marketplace, forecast to hit \$400B by 2020

Complex Drugs for Complex Illnesses



Oncology Rheumatoid Arthritis Multiple Sclerosis HIV/AIDS IBD ESRD IVIG Hemophilia Hepatitis C Growth Hormone Cardiovascular Transplant Other

Source: UnitedHealth Group, 2014

Notes: Includes spending under the pharmacy and medical benefit; IBD = inflammatory bowel disease, ESRD = end-stage renal disease, IVIG = intravenous immunoglobulin

Increase in Drug Costs

Wonkblog


Specialty drugs now cost more than the median household income

Α ₽ 235 Most Read By Carolyn Y. Johnson November 20 💟 🎔 Follow @carolynyjohnson Average annual price of specialty drugs 1 Dow and DuPont, two of America's oldest giants, to \$53.384 merge in jaw-dropping megadeal DraftKings, FanDuel lose big, ordered to shut down anDuel in New York 3 There's a crisis at Chipotle \$18,2 I asked psychologists to analyze Trump supporters. This is what I learned. 0 2005 2013 Why do doctors choose a \$2,000 cure when a \$50 Source: AARP Public Policy Institute one is just as good? WAPO.ST/WONKBLOG

Berkrot B. Global drug spending to hit \$1.4 trillion in 2020: IMS. Reuters. Nov 18 2015. Johnson C. Specialty drugs now cost more than the median household income. The Washington Post. Nov 20 2015.

National Drug Spend

Traditional vs. Specialty Growth



Source: Prime Therapeutics 2012 Drug Trend Insights Report

Complex Management: Traditional vs. Specialty Pharmacy

Operations

- Claims adjudication
- Accounts receivable
- Billing and collection
- Prescription dispensing & delivery
- Cold chain shipping systems*

Patient Support

- Adherence packaging
- 24/7 pharmacist access*
- Benefits investigation*
- Prior authorization*
- Financial Assistance*

Patient Care Management

- Call center, patient education*
- Complex disease state management*
- Compliance management*
- Training patients on therapy complexity*
- Data reporting*


* Indicates "specialty" differentiated services

What's coming?

- 771 compounds in trials for Oncology
- >100 for Rheumatology
- 82 medications for Alzheimer's
- 44 medications and vaccines for HIV
- 38 medications for Multiple Sclerosis
- 27 medications for Parkinson's
- 14 compounds in late-stage trials for Hepatitis C


Specialty **cholesterol**, **hypertension**, and **diabetes** medications are now entering the pipeline

2014 Drug Dispensing Trend: Traditional vs. Specialty Drugs, by PBM



Source: Pembroke Consulting analysis of company drug trend reports. CVS Health and Catamaran figures represent each PBM's overall book of business. Express Scripts figures represent commercially insured beneficiaries only.

Pharmacy Industry Revenues: Traditional vs. Specialty Drugs, 2010-2020



Figures in billions Source: Pembroke Consulting estimates

Specialty Pharmaceuticals

Summary

Background

- \$130 billion national market (20% annual growth)
- Treat chronic, high-cost diseases
- Require dedicated clinical & administrative resources for complex "high touch" therapies
- Require special access to (1) specific drugs and (2) insurance contracts/reimbursement
- For many complex patients with chronic disease, deriving value from specialty drugs is key to overall health management

Goals

- Enhance continuum of care
- Capture incremental revenue & margin
- Leverage integrated delivery network (IDN)
- Improve physician office satisfaction & efficiency
- Improve patient experience & outcomes

What are we talking about when we say "Specialty Pharmacy"?

•An immediate revenue opportunity

Long-term patient health care outcomes strategy



About the Health-System

- •Multi-hospital, regional referral health-system
- •Serves > 600,000 patients per year in the Upper Midwest
- •Six Cancer Centers
- •Regional outreach clinics in approximately 65 locations


WHealth



UW Health

Home to a homegrown Specialty Pharmacy program

Percentage of Total Drug Spend: Specialty Pharmaceuticals




UW Health Specialty Pharmacy Services Current Personnel

- 8 FTE Prior Authorization Coordinators
- 8 FTE Pharmacy Technicians
- 6 FTE Pharmacist
- 3 FTE Fiscal/Accounts Payable
- 1 FTE Medication Assistance Program
- 1 FTE Manager

27 FTE Total support for Specialty Pharmacy operations


UW Health Specialty Pharmacy Services

5 Year Return on Investment



FY09 to FY17

Positive Growth Driven by Specialty & Supply Chain



UW Health Specialty Pharmacy Program Adherence Snapshot

HIV	 54,750 medication days dispensed Aggregate MPR: 96.9% Literature metric: 90-95% 		
Oral Oncology	 6,176 medication days dispensed Aggregate MPR: 92.4% Literature metric: none 		
Multiple Sclerosis	 24,836 medication days dispensed Aggregate MPR: 93.6% (target >90%) Literature metric: 80% 		
Inflammatory Conditions	 82,652 medication days dispensed Aggregate MPR: 89.2% (target >80%) Literature metric: 80% 		

March 2016 Patient Satisfaction Scores

- 99.3% of patients reported that pharmacy services <u>met</u> or exceeded expectations
- 90.3% of patients reported that they'd either recommend or strongly recommend a family member to use UW Health Pharmacy Services



UW Health Hepatitis C Case Study

Outcomes and Performance Measurement

Literature reported specialty pharmaceutical (Hep C) discontinuation rates:

- Specialty Pharmacy: 5.9-8.5%
- Retail Pharmacy: 8.8%

UW Health adherence and health outcomes:

- Courses of Hepatitis C treatment initiated: 20
- Sustained virologic response (SVR): 93% \rightarrow 100%
- Therapy completion: 100%

The true benefit of driving utilization to specialty pharmacies can be seen from the better clinical outcomes that a specialized pharmacy can provide.

Our Health System Reality

- •5% of our patients comprise 50% of our total medical expense
- •Disproportionately specialized patient population
- •Population health expectations continue to mount
- Increasingly accountable for outcomes
- •Comprehensive patient management will be necessary
- •Specialty pharmacy is no longer niche
- •Most to all risk will eventually be carved in

The value of retail and specialty pharmacy to a health system goes way beyond the ROI ofthe pharmacy business. It includes success of the organization in a value-based payment world.

About the Health-System


- •Nine regional hospitals
- •6.62 million patient visits per year
- •\$7.2 billion operating revenue
- •1440-bed main campus



Cleveland Clinic

...and our "secret sauce"

2016 CC Pharmaceutical Purchase Overview



Source: Pharmacy Purchasing Datawarehouse YTD through Q2 2015 (Annualized)

Why We Entered the Market

- •\$153B marketplace by 2018
 - 50% of new drugs are specialty
 - PhRMA investment in pipeline
- •20% annual growth
- Population health management
 \$ Drugs > \$ Medical
- •Service line integration




Disrupting the Market


- •Concierge patient care
- •EMR integration
 - Fully documented in Epic
- Improve health system efficiency
 - Pre authorizations
 - Workflow simplification
- •Clinical program integration
- Proof of concept / data warehouse

Think Different	
Think Different	


Cleveland Clinic Timeline



Specialty Revenue Monthly Trending (millions \$)



Prescription Volume Monthly Trend (# Rx)



Accreditation



CERTIFICATE OF Full Accreditation is awarded to The Cleveland Clinic Foundation 9500 Euclid Avenue / AC5b-137 Cleveland, Ohio 44195

for compliance with Specialty Pharmacy Accreditation Program

pursuant to the Specialty Pharmacy, 2.1 Effective from the 08/01/2016 through the 08/01/2019

Kylanne Aran

Kylanne Green President & Chief Executive Officer




URAC accreditation is assigned to the organization and address named in this certificate and is not transferable to subcontractors or other affiliated entities not accredited by URAC.

URAC accreditation is subject to the representations contained in the organization's application for accreditation. URAC must be advised of any changes made after the granting of accreditation. Failure to report changes can affect accreditation status.

This certificate is the property of URAC and shall be returned upon request.

Data Warehouse



Patient Advantages

- Concierge onboarding
- Coordination of insurance benefits
- •Facilitate grant / foundation access
- •Proactive refill management
- •Adherence monitoring



Provider Advantage

- •Electronic Health Record (EHR) documentation
 - Onboarding
 - Ongoing
- •Prior authorization management
- •Ease of access
 - Shared electronic medical record
 - E-prescribing
 - Electronic prior authorizations

Multiple Sclerosis (MS): Coordination of Care

•MS Turn-Around Time (TAT)

- Patients receive medication within 3 business days after receipt of prescription

- TAT includes prior authorization processing

•MS Patients on Tecfidera Therapy

- 90% of CCF Specialty Pharmacy patients initiated on Tecfidera remain on therapy due to aggressive side-effect management protocols

Hepatitis C Coordination of Care

- •After PA is approved, patients receive their antivirals within 1-2 business days
- •Upon discontinuation of therapy, all HCV patients are referred back to their providers for follow-up appointments



Hepatitis C Patient

	Provider	Department	Encounter #	Center	
1/6/2015 12:19 PM LI	UCIA VESCERA, PHARMACIST	Pharm Specialty	310254479	None	
Patient Info					
Patient Name	Sex	•		DOB	
Varga, Terry D (33216149)	Male			10/25/1954	
IC Sensitive Note LUCIA VESCERA, PHARMACIST 1/6/2015 1					
Cleveland Clinic Specialty Pharmacy received was approved 01/29/14, through 3/23/14. Patie Foundation (PAN-F). I submitted the essential is aware and delivery will be made for 01/07/15 up with the office to confirm start date. Thank you, Lucia Vescera, PharmD RPH Cleveland Clinic Specialty Pharmacy P: 216-448-7732	ents co-pay was \$3,685.54. Be financial information relative to	eing that he is medicare I o the patient and received	he qualifies for patient assista I a \$10,000 grant to cover the	nce through Patient Assess Network remaining of his co-pays. The patient	
No Known Allergies Date Verified: 12/17/2014					
	Patient	assistance.			
No Known Allergies Date Verified: 12/17/2014 Reason for Visit Patient Update	Patient	assistance.			
No Known Allergies Date Verified: 12/17/2014 eason for Visit Patient Update hutpatient Encounter Meds: End of Enc- 1/6/2015					
No Known Allergies Date Verified: 12/17/2014 eason for Visit Patient Update	Take 1	tablet by mouth once daily.			
No Known Allergies Date Verified: 12/17/2014 eason for Visit Patient Update utpatient Encounter Meds: End of Enc- 1/6/2015 ledipasvir-sofosbuvir (HARVONI) 90-400 mg tab sulfamethoxazole-trimethoprim (BACTRIM DS) 8	Take 1 800-160 mg per tablet Take 1	tablet by mouth once daily. tablet by mouth every Mono	lay,Wednesday,Friday.		
No Known Allergies Date Verified: 12/17/2014 eason for Visit Patient Update utpatient Encounter Meds: End of Enc- 1/6/2015 ledipasvir-sofosbuvir (HARVONI) 90-400 mg tab sulfamethoxazole-trimethoprim (BACTRIM DS) & PROGRAF 1 mg capsule	Take 1 800-160 mg per tablet Take 1 Take 1	tablet by mouth once daily. tablet by mouth every Mono capsule by mouth twice dai	lay,Wednesday,Friday. ly.		
No Known Allergies Date Verified: 12/17/2014 eason for Visit Patient Update utpatient Encounter Meds: End of Enc- 1/6/2015 ledipasvir-sofosbuvir (HARVONI) 90-400 mg tab sulfamethoxazole-trimethoprim (BACTRIM DS) & PROGRAF 1 mg capsule ALPRAZolam (XANAX) 0.5 mg tablet	Take 1 800-160 mg per tablet Take 1 Take 1 Take 0	tablet by mouth once daily. tablet by mouth every Mono capsule by mouth twice dai 5 mg by mouth at bedtime a	lay,Wednesday,Friday. Iy. as needed.		
No Known Allergies Date Verified: 12/17/2014 eason for Visit Patient Update Dutpatient Encounter Meds: End of Enc. 1/6/2015 ledipasvir-sofosbuvir (HARVONI) 90-400 mg tab sulfamethoxazole-trimethoprim (BACTRIM DS) & PROGRAF 1 mg capsule ALPRAZolam (XANAX) 0.5 mg tablet oxyCODONE HCI 15 mg immediate release table	Take 1 800-160 mg per tablet Take 1 Take 1 Take 0 et Take 1	tablet by mouth once daily. tablet by mouth every Mono capsule by mouth twice dai 5 mg by mouth at bedtime a 5 mg by mouth every 4 hour	lay,Wednesday,Friday. Iy. as needed.		
No Known Allergies Date Verified: 12/17/2014 Patient Update Putpatient Encounter Meds: End of Enc. 1/6/2015 Iedipasvir-sofosbuvir (HARVONI) 90-400 mg tab sulfamethoxazole-trimethoprim (BACTRIM DS) § PROGRAF 1 mg capsule ALPRAZolam (XANAX) 0.5 mg tablet oxyCODONE HCI 15 mg immediate release table testosterone 25 mg/ 2.5g (1%) TRANSDERM. GIP	Take 1 800-160 mg per tablet Take 1 Take 1 Take 1 take 1 take 1 Take 1 k Apply 2	tablet by mouth once daily. tablet by mouth every Monc capsule by mouth twice dai .5 mg by mouth at bedtime a 5 mg by mouth every 4 hour 2.5 g to affected area.	lay,Wednesday,Friday. Iy. as needed.		
No Known Allergies Date Verified: 12/17/2014 Reason for Visit Patient Update Dutpatient Encounter Meds: End of Enc- 1/6/2015 ledipasvir-sofosbuvir (HARVONI) 90-400 mg tab sulfamethoxazole-trimethoprim (BACTRIM DS) & PROGRAF 1 mg capsule ALPRAZolam (XANAX) 0.5 mg tablet oxyCODONE HCI 15 mg immediate release table testosterone 25 mg/ 2.5g (1%) TRANSDERM. GIP Oxycodone 60 mg ORAL Tb12	Take 1 800-160 mg per tablet Take 1 Take 1 0 take 0 et Take 1 k Apply 2 Take 1 take 1 Take 1	tablet by mouth once daily. tablet by mouth every Mono capsule by mouth twice dai 5 mg by mouth at bedtime : 5 mg by mouth every 4 hour 2.5 g to affected area. y mouth three times daily.	łay,Wednesday,Friday. ly. as needed. s as needed.		
No Known Allergies Date Verified: 12/17/2014 Reason for Visit Patient Update Dutpatient Encounter Meds: End of Enc- 1/6/2015 ledipasvir-sofosbuvir (HARVONI) 90-400 mg tab sulfamethoxazole-trimethoprim (BACTRIM DS) & PROGRAF 1 mg capsule ALPRAZolam (XANAX) 0.5 mg tablet oxyCODONE HCI 15 mg immediate release table testosterone 25 mg/ 2.5g (1%) TRANSDERM. GIP Oxycodone 60 mg ORAL Tb12 Acyclovir 400 mg ORAL tablet	Take 1 800-160 mg per tablet Take 1 Take 0 et Take 1 k Apply 2 Take 1 Take 1 take 1 Take 1 Take 1 Take 1	tablet by mouth once daily. tablet by mouth every Mono capsule by mouth twice dai 5 mg by mouth at bedtime a 5 mg by mouth every 4 hour 2.5 g to affected area. by mouth three times daily. tablet by mouth twice daily.	łay,Wednesday,Friday. ly. as needed. s as needed.		
No Known Allergies Date Verified: 12/17/2014 Reason for Visit Patient Update Dutpatient Encounter Meds: End of Enc- 1/6/2015 ledipasvir-sofosbuvir (HARVONI) 90-400 mg tab sulfamethoxazole-trimethoprim (BACTRIM DS) & PROGRAF 1 mg capsule ALPRAZolam (XANAX) 0.5 mg tablet oxyCODONE HCI 15 mg immediate release table testosterone 25 mg/ 2.5g (1%) TRANSDERM. GIP Oxycodone 60 mg ORAL Tb12	Take 1 800-160 mg per tablet Take 1 Take 1 Take 0 et Take 1 k Apply 2 Take 1 Take 1 Take 1 Take 1 Take 1	tablet by mouth once daily. tablet by mouth every Mono capsule by mouth twice dai 5 mg by mouth at bedtime : 5 mg by mouth every 4 hour 2.5 g to affected area. y mouth three times daily.	łay,Wednesday,Friday. ly. as needed. s as needed.		
No Known Allergies Date Verified: 12/17/2014 Reason for Visit Patient Update Dutpatient Encounter Meds: End of Enc- 1/6/2015 ledipasvir-sofosbuvir (HARVONI) 90-400 mg tab sulfamethoxazole-trimethoprim (BACTRIM DS) & PROGRAF 1 mg capsule ALPRAZolam (XANAX) 0.5 mg tablet oxyCODONE HCI 15 mg immediate release table testosterone 25 mg/ 2.5g (1%) TRANSDERM. GIP Oxycodone 60 mg ORAL Tb12 Acyclovir 400 mg ORAL tablet amlodipine besylate(NORVASC 2.5 MG TAB) CENTRUM SILVER TAB	Take 1 800-160 mg per tablet Take 1 Take 1 Take 0 et Take 1 k Apply 2 Take 1 Take 1 Take 1 Take 1 Take 1 Take 1	tablet by mouth once daily. tablet by mouth every Mono capsule by mouth twice dai 5 mg by mouth at bedtime a 5 mg by mouth every 4 hour 2.5 g to affected area. by mouth three times daily. tablet by mouth twice daily. ne(1) tablet daily.	łay,Wednesday,Friday. ly. as needed. s as needed.		
No Known Allergies Date Verified: 12/17/2014 Reason for Visit Patient Update Dutpatient Encounter Meds: End of Enc- 1/6/2015 Iedipasvir-sofosbuvir (HARVONI) 90-400 mg tab sulfamethoxazole-trimethoprim (BACTRIM DS) 8 PROGRAF 1 mg capsule ALPRAZolam (XANAX) 0.5 mg tablet oxyCODONE HCI 15 mg immediate release table testosterone 25 mg/ 2.5g (1%) TRANSDERM. GIP Oxycodone 60 mg ORAL Tb12 Acyclovir 400 mg ORAL tablet amlodipine besylate(NORVASC 2.5 MG TAB)	Take 1 800-160 mg per tablet Take 1 Take 1 Take 0 et Take 1 k Apply 2 Take 1 Take 1 Take 1 Take 1 Take 1 Take 1	tablet by mouth once daily. tablet by mouth every Mono capsule by mouth twice dai 5 mg by mouth at bedtime a 5 mg by mouth every 4 hour 2.5 g to affected area. by mouth three times daily. tablet by mouth twice daily. ne(1) tablet daily.	łay,Wednesday,Friday. ly. as needed. s as needed.		

Heart Transplant Patient

Patient Update	refill encounter
all Documentation LUCIA VESCERA, PHARMACIST 11/11/2014 4:43 PM Signed	
	he is hereine consists the structure of Window has at his source and source like / attaining their d. Che source also is taking
two doses of her furosemide daily with no relief. I am concerned the appointment this Thursday (11/13/14). I encouraged her to share t	he is having weight fluctuations, difficulty breathing, and swelling/retaining fluid. She says she is taking at she is taking a higher dose of lasix than I see on her epic mar with minimal relief. She has an hese concerns at her visit.
Thank you,	
Lucia Vescera, PharmD	
Pharmacist, Specialty Pharmacy	
r harnaolot, opolary r harnaoy	
ledications	
ranitidine (ZANTAC 75) 75 mg tablet	Take 1 tablet by mouth once daily.
tacrolimus (HECORIA) 1 mg capsule	Take 6 capsules by mouth twice daily.
traZODone (DESYREL) 50 mg tablet	Take 1.5 tablets by mouth daily at bedtime.
calcium-cholecalciferol, D3, (OSCAL+D 250) 250-125 mg-unit per	Take 1 tablet by mouth twice daily.
tablet	Take I tablet by mount whee daily.
amLODIPine (NORVASC) 5 mg tablet	Take 1 tablet by mouth once daily.
predniSONE (DELTASONE) 5 mg tablet	Take 3 tablets by mouth once daily.
Ferrous Sulfate 325 mg (65 mg iron) tablet	Take 1 tablet by mouth daily with breakfast.
potassium chloride SR (K-DUR, KLOR-CON) 20 mEq tablet	Take 1 tablet by mouth once daily.
tacrolimus (HECORIA, PROGRAF) 0.5 mg capsule	Take 1 capsule by mouth every morning. V42.1 heart transplant
furosemide (LASIX) 20 mg tablet	Take 1 tablet by mouth once daily.
warfarin (COUMADIN) 1 mg tablet	Take as directed by Cournadin clinic Currently taking one 1mg tab and one 5mg tab for total of 6mg)
insulin glargine (LANTUS SOLOSTAR) 100 unit/mL (3 mL) inpn	24 units SQ DAILY AT 8AM
Insulin Lispro, Human, (HUMALOG KWIKPEN) 100 unit/mL inpn	Inject 10 U with breakfast, 12 U with unch, 9 U with dinner
rosuvastatin (CRESTOR) 10 mg tablet	Take 1 tablet by mouth daily at bedtime.
Insulin Needles, Disposable, (NANO PEN NEEDLE) 32 x 5/32 " ndle	QAC/HS and pm.
Lancets (FREESTYLE LANCETS) lancets	For testing 4 times daily.
blood sugar diagnostic (FREESTYLE LITE STRIPS) test strip	Use as instructed before meals and at bedtime. Dx steroid-induced DM (4 x Daily)
lisinopril 20 mg tablet	Take 1 tablet by mouth once daily.
warfarin 5 mg tablet	Take 1 tablet by mouth once daily.
esomeprazole 40 mg capsule	Take 1 capsule by mouth once daily.
traMADol 50 mg tablet	Take 1 tablet by mouth every 8 hours as needed for Pain.
magnesium oxide 400 mg tablet	Take 2 tablets by mouth twice daily.
sulfamethoxazole-trimethoprim 800-160 mg per tablet	Take 1 tablet by mouth every Monday,Wednesday,Friday.
ergocalciferol, vitamin D2, 50,000 unit capsule	Take 1 capsule by mouth MON and THU.
enoxaparin 80 mg/0.8 mL syrg	Inject 0.7 mL subcutaneously q 12 HR. DO NOT TAKE THE NIGHT BEFORE OR THE MORNING OF YOUR BIOPSIES.
mycophenolate mofetil 250 mg capsule	Take 4 capsules by mouth every 12 hours.

Oncology Patient

Visit Report
🖶 Back 😰 🚔 🖺 🎕 - 🗳
Patient called and has questions with regards to his medication. Please call before 1:00pm or after 3:00pm. Thank you
ANNIE TRAN, PHARMACIST 12/10/2014 4:45 PM Signed Specialty technician Camarri worked diligently to overturn the denial by Johnson & Johnson, and her appeal was approved! Pt has been approved for Zytiga for one year, and will not have any out-of-pocket costs for this medication. Pt is thrilled, and extremely grateful.
Pt actually chose to come by tomorrow afternoon 12/11 to our pharmacy at the CCAC in Beachwood to pick up his medication. I will counsel him on Zytiga at that time, and ensure that he has his prednisone from Costco. Dr. r, when did you want him to start his medication?
Annie Tran, PharmD Clinical Pharmacist, <i>Oncology, Growth Hormone</i> Cleveland Clinic Specialty Pharmacy P: (216) 448-7732, F: (216) 448-5601 Ext 8-5421
ANNIE TRAN, PHARMACIST 12/10/2014 1:10 PM Signed We attempted to apply patient for free Zytiga through Johnson & Johnson, and due to his income, pt is not eligible for their program. J&J has income limits of \$62,920 for a household of two, and while they exceed that by less than \$3,000, they are not willing to adjust for out-of-pocket medical expenses. Pt is very concerned about this situation, and cannot afford this medication on his own, especially given his wife's declining health. We are in process of appealing this decision with J&J, given that the pt is retired and fully uninsured.
Pt asked if there are other options that could be considered by Dr. r while we are waiting for the appeal, and we stated we would look into it for him. From a financial standpoint, it does look like he would qualify for Xtandi (which has a \$100K income limit on their free drug program). I do not know if pt would be a candidate for Xtandi, but it may be something to consider, especially if J&J declines our appeal.
Annie Tran, PharmD Clinical Pharmacist, <i>Oncology, Growth Hormone</i> Cleveland Clinic Specialty Pharmacy P: (216) 448-7732, F: (216) 448-5601 Ext 8-5421
ANNIE TRAN, PHARMACIST 12/10/2014 12:52 PM Addendum Cleveland Clinic Specialty Pharmacy received a prescription for Zytiga on 12/03/14 from Dr. Senefits investigation revealed that pt has no prescription coverage at all. We have been working diligently on getting free drug through Patient Assistance for him. Will continue to keep the clinic posted on status.

Outcomes: Focused on ED Use

- •Population: CCF Multiple sclerosis patients
- •Metric: ED utilization pre and post enrollment
- •Result: Reduction in post enrollment ED utilization
 → 13% to 8%

Outcomes

•Population: Ohio Medicaid

- ED utilization compared to outside SRx
- Measured over a 4 month period
 - \rightarrow CCF SRx: 25%
 - → Outside SRx: 50%

Outcomes

•CCF Employee Health Plan

- Compare ED utilization vs outside SRx
- Measured over a 4 month period

 \rightarrow CCF SRx 12.9%

→ Outside SRx 17.2%

Where does specialty pharmacy fit on the quality spectrum?

A strong internal specialty pharmacy program provides value to health systems no matter the payment model(s)



Source: PricewaterhouseCoopers

Eight Reasons to Invest in an Internal Specialty Pharmacy Program

Revenue	Supply Chain Efficiency	Improved Patient Health Outcomes	Patient and Provider Experience
ČS.		S.C.	
ACO/Capitation Risk Avoidance	Internal Retail Pharmacy Growth	Continuity of Care	Leverage

Key Takeaways

- 1. Accountability for improved health outcomes is the long-term financial opportunity
- 2. Management of the entire patient, rather than a few services, is our next reality
- 3. Pharmacy understands cost drivers of specialty populations and is a key partner
- 4. Involvement of pharmacy in value-based contracting should be a priority from the beginning

Specialty Pharmacy: A Key to Organizational Success in Population Health Management

Scott Knoer, PharmD, MS, FASHP Chief Pharmacy Officer, Cleveland Clinic

Steve Rough, MS, RPh, FASHP Director of Pharmacy, University of Wisconsin Health

The speakers have no actual or potential Conflict of Interest in relation to this presentation.